Gide, counsel to ENYO Pharma on its EUR 40 million Series B funding round
6 June 2018
Deals | France | M&A | Private Equity
Gide has advised ENYO Pharma on its EUR 40 million Series B round of financing from US and European investors. ENYO Pharma is a clinical stage biotech company developing innovative drug candidates by mimicking virus strategies to modulate host cellular functions. This very significant funding will enable the company to finance the two first Phase II clinical trial of its EYP001 asset in both chronic HBV and NASH. A second asset is also expected to enter the clinic by 2019.
This operation was led by OrbiMed, followed by Andera Partners and Bpifrance Large Venture as new shareholders. Existing shareholders Sofinnova Private Capital VII, Morningside Venture Investments, InnoBio and Inserm Transfert Initiative, also took part in this funding round.
Gide's team advising ENYO Pharma was led by counsel Matthias Grolier, with associates Arnaud de Keulenaer and Hélène Thomelin on corporate aspects.